Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. Ashina M, et al. Among authors: josiassen mk. Lancet Neurol. 2022 Jul;21(7):597-607. doi: 10.1016/S1474-4422(22)00185-5. Lancet Neurol. 2022. PMID: 35716692 Clinical Trial.
Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
Hobart M, Skuban A, Zhang P, Josiassen MK, Hefting N, Augustine C, Brewer C, Sanchez R, McQuade RD. Hobart M, et al. Among authors: josiassen mk. Curr Med Res Opin. 2018 Apr;34(4):633-642. doi: 10.1080/03007995.2018.1430220. Epub 2018 Jan 25. Curr Med Res Opin. 2018. PMID: 29343128 Clinical Trial.
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
McAllister P, Winner PK, Ailani J, Buse DC, Lipton RB, Chakhava G, Josiassen MK, Lindsten A, Mehta L, Ettrup A, Cady R. McAllister P, et al. Among authors: josiassen mk. J Headache Pain. 2022 Feb 7;23(1):22. doi: 10.1186/s10194-021-01376-7. J Headache Pain. 2022. PMID: 35130832 Free PMC article. Clinical Trial.
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. Barbanti P, et al. Among authors: josiassen mk. J Headache Pain. 2022 Dec 2;23(1):153. doi: 10.1186/s10194-022-01521-w. J Headache Pain. 2022. PMID: 36460983 Free PMC article. Clinical Trial.
Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
Ashina M, Lanteri-Minet M, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B, Pozo-Rosich P. Ashina M, et al. Among authors: josiassen mk. Cephalalgia. 2023 May;43(5):3331024231170807. doi: 10.1177/03331024231170807. Cephalalgia. 2023. PMID: 37125484 Free article. Clinical Trial.
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
Ailani J, McAllister P, Winner PK, Chakhava G, Josiassen MK, Lindsten A, Sperling B, Ettrup A, Cady R. Ailani J, et al. Among authors: josiassen mk. BMC Neurol. 2023 Sep 6;23(1):318. doi: 10.1186/s12883-023-03368-3. BMC Neurol. 2023. PMID: 37674117 Free PMC article. No abstract available.
17 results